 |
Accelevir Diagnostics provides specialized vector shedding analysis for investigational gene therapy programs, generating quantitative data required for FDA and EMA regulatory submissions. Our CLIA-certified bioanalytical laboratory applies validated qPCR and digital PCR platforms with specialized expertise in viral vector characterization to support clinical development timeline.
Regulatory-grade vector shedding and biodistribution analysis from a CLIA-certified bioanalytical laboratory.
Vector and viral shedding — the release of vector genome copies into bodily fluids and excreta — is a regulatory requirement for gene therapy submissions under the FDA’s 2015 guidance and the EMA/ICH framework. Clinical vector shedding levels inform subject containment measures and precaution durations.
Vector shedding data also complement biodistribution analysis, supporting interpretation of systemic dissemination relative to targeted tissue delivery, including skeletal or cardiac muscle expression sites.
Vector shedding data is required by FDA and EMA for gene therapy submissions and informs patient containment.
Regulatory-ready data.
Our laboratory offers high-sensitivity qPCR and droplet digital PCR detection for multi-serotype AAV analysis. We quantify vector genome copies across bodily fluids, including saliva, urine, feces, and semen, using methods that can achieve sensitivity below 1,000 copies/ml, with performance varying across matrix complexity. Tissue-specific vector quantification supports integrated tissue distribution assessments in both nonclinical and clinical studies.
Lentiviral programs are supported through validated workflows, persistence monitoring, and integration-related assessments.
Analysis of mRNA persistence and degradation supports LNP-based therapeutic programs. We assess tissue-specific delivery confirmation and clearance kinetics, recognizing that mRNA typically demonstrates more rapid clearance kinetics than DNA-based vectors due to inherent RNA instability, while still requiring documented shedding characterization for regulatory submissions.
Accelevir processes comprehensive vector shedding assessments across a comprehensive range of sample matrices:
We maintain multi-species compatibility across rodent, NHP, and human samples with automated nucleic acid extraction protocols, ensuring consistent yield and reproducibility. Sensitivity specifications are matrix-dependent; semen and feces require higher LOQ thresholds due to inherent inhibitors, whereas saliva and urine achieve detection limits in the tens-to-hundreds-of-copies-per-mL range.
Absolute quantification at low copy numbers without standard-curve dependence.
Validated LOD/LLOQ characterization per matrix type.
Vector integrity assessment across key functional domains and integration analysis.
Functional particle characterization where required for safety evaluation.
Study stopping criteria are predefined in the protocol to align with the Sponsor’s regulatory guidance. Custom sampling schedules are aligned with vector type, doses, and dosing parameters.
Data analysis includes vector clearance kinetics, magnitude of shedding over time, and statistical evaluation of inter-subject variability.
Our team supports IND/CTA submissions with scientific interpretation addressing hypothetical risk scenarios. We provide ongoing consultation throughout clinical development, helping sponsors address root cause analysis when unexpected persistence is observed.
Our work directly supports IND-enabling and clinical submissions across modern gene therapy modalities.
Established across AAV, lentiviral, and mRNA-based gene therapy vectors.
Ongoing consultation from study design through regulatory review.
“With your (Accelevir’s) support of [our] therapeutic vaccine trial, we were able to quickly generate unbiased data with advanced molecular assays to evaluate a novel T cell-based therapeutic vaccine in a randomized clinical trial. Given our success working with your group, we have several planned studies testing novel interventions.”
“Over the course of our interactions, we have been impressed by the deep expertise at Accelevir with ultra-rare target detection and in supporting both research studies and clinical trials. We look forward to continuing to work with your group.”
“As an in vivo CRO, we rely heavily on strong bioanalytical partners—and working with Accelevir has truly elevated the quality of our studies. They feel like an extension of our team, consistently delivering high-quality, reliable data quickly and giving our sponsors real confidence as they move their programs forward.”
“Your assay development and refinement exemplifies the power of our platforms … by thoughtfully leveraging the unique precision, sensitivity, single template multiplexing, and linkage determination capabilities of digital PCR.”
Clearance kinetics vary by vector type and sample matrix. These are general estimates based on published clinical data; actual clearance kinetics depend on vector type, serotype, dose, route of administration, and individual patient factors. Most bodily fluids show shedding clearance within 2–4 weeks post-administration, while PBMCs may demonstrate detectable vector genomes for 8–12 weeks.
These are general estimates based on published clinical data; actual clearance kinetics depend on vector type, serotype, dose, route of administration, and individual patient factors Semen requires extended monitoring — the majority of participants in published AAV gene therapy programs achieve semen clearance by 6 months, though individual variation and extended monitoring may be required.
Standard protocols include the collection of blood, saliva, urine, feces, and semen. Sampling frequency is dense during the first few days post-treatment when peak vector shedding occurs, then tapers to weekly or monthly intervals until three consecutive samples demonstrate insignificant levels below LOD.
Our validated qPCR and gene therapy biodistribution PCR platforms achieve LOD specifications below 1,000 copies/mL for standard fluid matrices such as urine and saliva. Semen and feces present higher detection thresholds due to matrix complexity and PCR inhibition. Digital PCR offers superior accuracy for low-copy quantification in challenging sample types.
Yes. Our documentation packages meet FDA, EMA, and ICH requirements. We provide scientific interpretation, kinetic analysis, and formatted data packages suitable for global regulatory review processes.
Partner with Accelevir to address your vector shedding analysis and AAV biodistribution assay requirements. Our scientific team provides consultation from study design through regulatory submission.